Aflibercept, ranibizumab, and bevacizumab for macular neovascularization secondary to age-related macular degeneration: a retrospective OCT-angiography study.

Int J Retina Vitreous · 2025 · PMC12532941 · PMID 41102864

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant

Minor differences between groups, such as the higher CRT reduction with aflibercept and greater BCVA improvement with bevacizumab, did not reach statistical significance in inter-group analysis ( p > 0.05, Table 3 ).

also in 111,027 other papers

showed a trendno p-value reported

The OCTA MNV flow area showed a trend similar to the ImageJ area: the proportion of patients with a stable flow was 52.0% for the aflibercept group, 60.0% for bevacizumab, and 61.8% for ranibizumab.

also in 53,322 other papers

may be significantno p-value reported

The potential clinical implications of this study may be significant.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.